Shares of hVIVO plc (LON:HVO – Get Free Report) rose 10% during trading on Monday . The company traded as high as GBX 22 ($0.27) and last traded at GBX 21.25 ($0.26). Approximately 7,804,669 shares were traded during mid-day trading, an increase of 164% from the average daily volume of 2,961,263 shares. The stock had previously closed at GBX 19.33 ($0.24).
hVIVO Price Performance
The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The company has a fifty day moving average price of GBX 20.01 and a 200 day moving average price of GBX 25.58. The company has a market capitalization of £129.27 million, a P/E ratio of 633.33 and a beta of 0.97.
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
- Five stocks we like better than hVIVO
- Compound Interest and Why It Matters When Investing
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 3 Steel Stocks Soaring After Tariff Announcements
- Investing In Automotive Stocks
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
